Texas Biomedical Research Institute

Donate by phone 210-210-9755

CORONAVIRUS (COVID-19)

Texas Biomed scientists are working to develop diagnostics, therapeutics and prevention methods of COVID-19. Critical research is needed to study this highly transmissible virus. Donations allow Texas Biomed to further its research to combat COVID-19 and help bring this pandemic to an end. Texas Biomed is a 501(c)(3) and will provide a tax receipt to all donors.

Coronavirus (COVID-19)

COVID-19 was declared a pandemic in March 2020 and still continues to threaten lives and livelihoods. When we first launched fundraising for COVID-19 research, no known cures or vaccines existed. As we all know, that has changed in record time thanks to the power of science and collaboration and YOU, our supporters!

We are proud that we were well positioned with the scientific resources and expertise to play a critical role in the development of vaccines and therapies, most notably by establishing animal models of COVID-19 and then capably running pre-clinical trials for numerous pharmaceutical companies, including for the Pfizer-BioNTech vaccine. Pre-clinical animal studies are required and the data they provided were essential to show the vaccine was safe and effective. We could not have developed those animal models without the overwhelming generosity and support from our community that rallied more than $5 million in donations in a week for this work!

Live-saving vaccines are now available, yet there is still an urgent need to answer many questions about this virus. As we learn more about the virus and how it behaves in the body, we aim to find even more ways to stop it in its tracks — especially since, as we have seen, it is incredibly sneaky and continues to mutate (as viruses do) to try to evade the vaccines and therapies developed so far. We are not letting up, not just for this disease, but all infectious diseases, and we continue to humbly ask for your support.

Texas Biomed’s mission is to eradicate infectious diseases around the world. As a private non-profit institution, we are providing a nimble and accelerated method for moving a drug from discovery to the market. Our track record includes research that has resulted in the first Ebola treatment, the first Hepatitis-C therapy and the first COVID-19 vaccine and antibody treatments.

Investment in Texas Biomed directly supports the country’s efforts to expedite development, stockpiling and ultimate use of new diagnostics, therapies and vaccines at the preclinical level. The fully integrated R&D plan for infectious disease research at Texas Biomed enables preclinical science to move from REACTING to outbreaks to PROACTIVELY planning ahead for the next one.